A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy
Phase 4
Completed
NCT03641560
| Condition | Metastatic Castration Resistant Prostate Cancer |
|---|
| Phase | Phase 4 |
|---|
| Sponsor | Astellas Pharma Inc |
|---|
| Status | Completed |
|---|
| Enrollment | 52 participants |
|---|
| Interventions | Enzalutamide, Androgen deprivation therapy (ADT) |
|---|
| Start date | Sep 19, 2018 |
|---|
| Completion date | Feb 20, 2024 |
|---|
| Results posted | Jan 23, 2025 |
|---|
Summary
The purpose of this study was to evaluate the safety and tolerability of enzalutamide in Indian patients with progressive mCRPC previously treated with docetaxel-based chemotherapy. This study also evaluated the effect of enzalutamide on prostate-specific antigen (PSA).
Number of Participants With Treatment- Emergent Adverse Events (TEAEs)
From first dose of study drug until 30 days after last dose (Up to 1899 days) · Participants
| Enzalutamide | 36 Participants |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.